Nanoparticle: A Promising Player in Nanomedicine and its Theranostic Applications for the Treatment of Cardiovascular Diseases
- PMID: 36681209
- DOI: 10.1016/j.cpcardiol.2023.101599
Nanoparticle: A Promising Player in Nanomedicine and its Theranostic Applications for the Treatment of Cardiovascular Diseases
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death around the world, a trend that will progressively grow over the next decade. Recently, with the advancement of nanotechnology, innovative nanoparticles (NPs) have been efficiently utilized in disease diagnosis and theranostic applications. In this review, we highlighted the benchmark summary of the recently synthesized NPs that are handy for imaging, diagnosis, and treatment of CVDs. NPs are the carrier of drug-delivery payloads actively reaching more areas of the heart and arteries, allowing them novel therapeutic agents for CVDs. Herein, due to the limited availability of literature, we only focused on NPs mechanism in the cardiovascular system and various treatment-based approaches that opens a new window for future research and versatile approach in the field of medical and clinical applications. Moreover, current challenges and limitations for the detection of CVDs has also discussed.
Copyright © 2023 Elsevier Inc. All rights reserved.
Similar articles
-
Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases.Antioxid Redox Signal. 2019 Feb 10;30(5):733-746. doi: 10.1089/ars.2017.7428. Epub 2018 Jan 30. Antioxid Redox Signal. 2019. PMID: 29228781 Free PMC article. Review.
-
Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases.Nanotheranostics. 2021 Jul 21;5(4):499-514. doi: 10.7150/ntno.62730. eCollection 2021. Nanotheranostics. 2021. PMID: 34367883 Free PMC article. Review.
-
Nanomedicine strategies for molecular targets with MRI and optical imaging.Future Med Chem. 2010 Mar;2(3):471-90. doi: 10.4155/fmc.10.5. Future Med Chem. 2010. PMID: 20485473 Free PMC article. Review.
-
Multifunctional role of nanoparticles for the diagnosis and therapeutics of cardiovascular diseases.Environ Res. 2024 Feb 1;242:117795. doi: 10.1016/j.envres.2023.117795. Epub 2023 Dec 2. Environ Res. 2024. PMID: 38043894 Review.
-
Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.Int J Mol Sci. 2022 Jan 26;23(3):1404. doi: 10.3390/ijms23031404. Int J Mol Sci. 2022. PMID: 35163328 Free PMC article. Review.
Cited by
-
Study on the Regulated Cell Death of Hypertrophic H9c2 Cells Induced by Au:Ag Nanoparticles.Int J Nanomedicine. 2025 Feb 3;20:1491-1507. doi: 10.2147/IJN.S491288. eCollection 2025. Int J Nanomedicine. 2025. PMID: 39925684 Free PMC article.
-
A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View.Curr Pharm Des. 2025;31(10):741-752. doi: 10.2174/0113816128347223241021111914. Curr Pharm Des. 2025. PMID: 39506444 Review.
-
Cardiovascular Toxicity of Metal-Based Nanoparticles.Int J Mol Sci. 2025 Jun 17;26(12):5816. doi: 10.3390/ijms26125816. Int J Mol Sci. 2025. PMID: 40565277 Free PMC article. Review.
-
RNA modification in cardiovascular disease: implications for therapeutic interventions.Signal Transduct Target Ther. 2023 Oct 27;8(1):412. doi: 10.1038/s41392-023-01638-7. Signal Transduct Target Ther. 2023. PMID: 37884527 Free PMC article. Review.
-
Assembly of ceria-Nrf2 nanoparticles as macrophage-targeting ROS scavengers protects against myocardial infarction.Front Pharmacol. 2025 Jan 10;15:1503757. doi: 10.3389/fphar.2024.1503757. eCollection 2024. Front Pharmacol. 2025. PMID: 39867660 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources